Dr. Sutton has been a member of the AIM community for several years and is one of our Conclave experts in the medical field. In the audio below, she provides an update on how the trial is proceeding. Dr. Sutton can be reached at https://www.raphaelmedicine.com/
Dr. Sutton clarifiesterms used above:
A contraindication is distinct from an adverse event following vaccination.
Contraindications — conditions under which vaccines should NOT be administered. Decided exclusively by the ACIP Advisory Committee on Immunization Practices. Many/most of whom have conflicts of interest. The trend is for states to pass vaccine mandates with no religious exemptions, no personal belief exemptions, and the medical exemptions must comply with the ACIP guidelines.
Most contraindications are from a person having anaphylaxis (severe, potentially life-threatening allergic reaction.) following a vaccine. So in other words, you have to be damaged before you can be exempt.Then a person is exempt from that ONE vaccine and still must take all others. There are a few contraindications for congenital immune deficiency, cancer and chemotherapy, recent blood or gamma globulin infusion, and severe allergies to egg or yeast, in addition to anaphylaxis. It is important to note that up to 20% of the people die who experience anaphylaxis. Regulations require a high bar to skip a vaccine — put your life on the line.
NY, ME, WV, MS, and CA currently allow only Med exempt based on ACIP guidelines, no relig exempt or personal belief exempt– great map here:
Vaccine studies for FDA approval are remarkably short — 4-42 days, with some phone follow up. There is no true saline inert placebo, but an adjuvant or another vaccine is the so-called placebo which accurately named is not a placebo but a comparator. The vaccine performs well in this match-up, as you might imagine In the vaccine insert the word ‘placebo’ is still used! Misleading!
The primary post-marketing follow up is the Vaccine Adverse Event Reporting System: VAERS. By design, doctors are required to report serious adverse events after vaccines, but the process is cumbersome and rarely accomplished. Patients may report adverse events. Reporting an event does not indicate causality. This data is not considered strong statistically, b/c it is passive reporting (not actively sought). It is not statistically strong. It is estimated only 1% -10% of all serious vaccine adverse events are reported to VAERS.
A grant was given to Harvard Pilgrim HMO to make adverse event reporting an automatic part of the electronic medical record. This would follow appointments, diagnoses, and lab results in the EMR after a vaccine. This system estimated the frequency of adverse events after vaccination was 1/39. The media/medicine statement is the serious adverse events from vaccines are 1/1 million. The grant never went to fruition, as the CDC colleagues stopped answering phone calls from the study leaders.
AEFI adverse event following immunization is a common term in the vaccine literature. This indicates a temporal relation between the vaccine and the adverse event.
The Institute of Medicine periodically evaluates adverse events to see if they are caused by the vaccines. There are 20-30 adverse EVENTS
which are called adverse EFFECTS of vaccines b/c there is consistently supportive evidence of causality. The other adverse events do not have enough information to determine if causally related or not to the vaccine.
The claim that adverse events are ‘not related to vaccines’ for the most part is not a scientific statement, because, there is not enough information to determine causality or lack of causality. That doesn’t stop media/medicine from making claims of ‘no relation.’ If a person were reading the science, they would have to say: we don;t know. Of course, that makes it harder to justify BROAD vaccine programs, especially MANDATED vaccines, which will impact the most vulnerable, and in those states without exemptions, they are impacted without a defense.
Over 110 years ago, at a time when medicine was not yet sufficiently advanced to have developed penicillin and the germ theory of medicine was still new, the Supreme Court of the United States made a ruling related to a citizen’s rights in healthcare that has remained largely unaddressed to this day. Over the century plus of time that has since passed the court has decided many critical cases revolving around individual rights that have never been squared with Jacobson.Jacobson v. Massachusetts, 197 U.S. 11 (1905).
A century ago many of our most sacred and fundamental rights were still being sorted out. Suffrage had not yet occurred, civil rights barely existed, critical cases on fundamental rights such as interstate travel and bodily privacy had not come into play and the administrative state that we live in today simply did not exist.
Today, under the guidance of an unelected administrative structure, many of the rights our Supreme Court has determined are fundamental under our Constitution are being denied. These fundamental rights are being denied, not out of prudence, they are being denied due to unfounded fear and intentional manipulation. So successful is this manipulation that even our esteemed Chief Justice, the Honorable Justice Roberts, was misled in a recent decision.
But all is not lost. In its wisdom, the Jacobsoncourt made clear that it never intended its decision to bar further review. To the contrary, the Court in Jacobsonspecifically stated:“Before closing this opinion, we deem it appropriate, in order to prevent misapprehension as to our views, to observe –perhaps to repeat a thought already sufficiently expressed, namely –that the police power of a State, whether exercised by the legislature or by a local body acting under its authority, may be exerted in such circumstances or by regulations so arbitrary and oppressive in particular cases as to justify the interference of the courts to prevent wrong and oppression.” (Id, 197 US 38)
In recent months, entire states have been imprisoned without due process and with the clear threat to impose such lockdowns again, interstate travel has been severely restricted, privacy rights have been devastated, numerous business takings without compensation, and many regulations being implemented without statutory process requirements under the guise of a health emergency that is roughly as dangerous as a seasonal influenza outbreak. The plaintiffs in this case have all been injured in various capacities by these unconstitutional actions, and without action by the Court, will be left without redress.
More terrifying, without action by the Court, the Court will be setting future precedent that will allow states to withhold fundamental Constitutional rights, in violation of US Supreme Court precedent, circumventing the various levels of scrutiny applied to such rights, and justify such actions under public health emergency orders without subjecting those orders to any real review –just trust the bureaucrats because they are the experts.
We humbly ask the Court in this case to:
Reaffirm its position as a coequal branch of the government.
2. Reaffirm the US Constitution is the supreme law of the land and that rights, especially fundamental rights, may not be abridged unless necessary to serve a compelling governmental interest, and that even then, those restrictions must be narrowly tailored to meet acompelling governmental interest.
3. Ensure there is an opportunity for redress under any emergency declaration
4. Recognize that the political process and operative orders are invalid if based on false or misleading information (cite rule making case in admin law) and recognize the criticality that all future emergency orders be based and maintained on clear, honest facts -particularly when such orders are infringing on Constitutional rights.
Underlying all of this, and the foundation of this case is this question: if an emergency can be declared without the appropriate level of review based on the rights being limited, and under the guise of that emergency all rights are only subject to a rational basis review, how then do any previous judicial opinions or Constitutional principles have any meaning whatsoever?
Further, if under the same circumstances different levels of scrutiny are applied to the various rights being limited under an emergency declaration than would otherwise be applicable, what is the value of having various levels of review?
Includes numerous conflicting relationships with Goldman Sachs, J.P. Morgan, Wellcome Trust (GlaxoSmithKline – GSK), Harvard, UPenn, Stanford, Merck, Novartis, Sanofi, McKinsey, London School of Economics (notorious promoter of communist ideology), Medtronic, MIT, Dell, Roche, Hoffman-Roche, VMware,
Moderna’s CEO Stephane Bancel and Chief Medical Officer Tal Zaks, MD, Phd have been big stock sellers for a year. Zaks was director of clinical development and translational medice for GLAXOSMITHKLINE (Wellcome Trust – co-owner of the Coronavisur Patent along with the Gates Foundation. THIS CONFLICT IS ALONE IS DISQUALIFYING & FRAUDULENT GIVE GLAXO’S RELATIONSHIP WITH THE PIRBRIGHT INSTITUTE (UK). https://heightzone.com/dr-tal-zaks/
Israeli Tal Zaks – Been only selling his Moderna stock (dumping) since Dec. 2019
This guy is evidently dumping his Moderna shares while he is promoting his supposed COVID vaccine.
That is illegal stock manipulation and should land him and his CEO in jail.
IRS No.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38753 | Film No.: 20787049
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences
Executives, non-executive directors and director nominee
The following table sets forth the name, age and position of each of our executives, non-executive directors and director nominee as of March 2, 2020.
Stéphane Bancel (1)
Chief Executive Officer and Director
Juan Andres (1)
Chief Technical Operations and Quality Officer
Chief Digital and Operational Excellence Officer
Chief Human Resources Officer
Lori Henderson, J.D. (1)
General Counsel and Corporate Secretary
Stephen Hoge, M.D. (1)
Lorence Kim, M.D. (1)
Chief Financial Officer
Tal Zaks, M.D., Ph.D. (1)
Chief Medical Officer
Noubar B. Afeyan, Ph.D. (4)(5)
Stephen Berenson (2)(3)
Robert Langer, Sc.D. (4)
Elizabeth Nabel, M.D. (4)(5)
François Nader, M.D.(5)
Paul Sagan (2)(3)
Moncef Slaoui, Ph.D.(5)
Sandra Horning, M.D.
Member of the Audit Committee
Member of the Compensation and Talent Committee
Member of the Nominating and Corporate Governance Committee
Member of the Product Development Committee
These relationships alone should fundamentally disqualify Moderna or any of its INTERLOCKING relationships from any involvement in Coronavirus.
“Since we nominated our first program in late 2014, we and our strategic collaborators have advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another 3 have open INDs. Our therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. We have assembled an exceptional team of approximately 700 employees and have established strategic alliances with leading biopharmaceutical companies, including AstraZeneca, Merck & Co., and Vertex Pharmaceuticals, as well as government-sponsored and private organizations focused on global health initiatives, including Biomedical Advanced Research and Development Authority, or BARDA, Defense Advanced Research Projects Agency, or DARPA, and the Bill & Melinda Gates Foundation. As of September 30, 2018, we have raised over $2.6 billion in total funding from our strategic collaborators and investors, and have cash, cash equivalents, and investments of $1.2 billion. As we unlock the inherent advantages of mRNA, we aim to address as many diseases and impact as many patients as our technology, talent, and capital permit.”
Stéphane Bancel has served as our Chief Executive Officer since October 2011 and a member of our board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA (Euronext: BIM). From July 2000 to March 2006, he served in various roles at Eli Lilly and Company (NYSE: LLY), including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly and Company, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel currently serves on the board of directors of Qiagen N.V. (NYSE: QGEN) and previously served on the boards of directors of BG Medicine, Inc. (OTCMKTS: BGMD) and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School. We believe that Mr. Bancel is qualified to serve on our board of directors because of his extensive leadership experience in the healthcare industry and experience as a director of public and private companies.
Juan Andres joined the Company in August 2017, and has served as our Chief Technical Operations and Quality Officer since August 2018. Before joining the Company, Mr. Andres worked at Novartis AG (NYSE: NVS) from
2005 to 2017, in various roles of increasing responsibility including serving as Global Head, Technical Operations (Manufacturing and Supply Chain), Global Head of Quality, and Global Head of Technical Research and Development. From 1987 to 1996, Mr. Andres served in various manufacturing, production, and quality roles at Eli Lilly and Company (NYSE: LLY), including as Vice President, Pharmaceutical Manufacturing. Mr. Andes has served as a member of the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO) since December 2019, and of Avantor, Inc. (NYSE: AVTR), since September 2019. Mr. Andres obtained a degree in pharmacy at the Universidad de Alcalá in Spain.
Marcello Damiani joined the Company in May 2015, and has served as our Chief Digital and Operational Excellence Officer since September 2018. From 2009 to 2015, Mr. Damiani held senior roles at bioMérieux (Euronext: BIM), including Senior Vice President and Group Chief Information Officer. Mr. Damiani holds an M.S. degree in Information Systems Architecture from the University of Toulouse, France and completed an international Executive M.B.A. program through TRIUM, an alliance of the London School of Economics, the NYU Stern Business School, and the HEC Paris School of Management, France.
Tracey Franklin has served as our Chief Human Resources Officer since October 2019. From 2004 to October 2019, Ms. Franklin held positions of increasing responsibility at Merck & Co., Inc., including most recently Vice President, HR Chief Talent and Strategy Officer. Ms. Franklin holds a B.A. in communication arts and sciences from Pennsylvania State University and a Masters in industrial and organizational psychology from Fairleigh Dickinson University.
Lori Henderson, J.D., has served as our General Counsel and Corporate Secretary since April 2018. From 2011 to 2018, Ms. Henderson served at Albany Molecular Research Inc. (Nasdaq: AMRI) first as Vice President, General Counsel and Corporate Secretary until 2014 and then as Senior Vice President, General Counsel and Head of Business Development. Prior to her time at AMRI, Ms. Henderson worked as a corporate attorney at Goodwin Procter LLP and as a General Counsel at other corporations. She received her J.D. from the George Washington University Law School and her B.A. in Business and Economics from Gordon College.
Stephen Hoge, M.D., joined the Company in January 2013 and has served as our President since February 2015. From 2010 to 2012, Dr. Hoge was a Partner at McKinsey & Company and a leader in the firm’s healthcare practice. From 2005 to 2010, he served in roles of increasing responsibility at McKinsey & Company. From 2004 to 2005, Dr. Hoge was a resident physician at New York University/Bellevue Hospital. Dr. Hoge has served on the board of directors of Axcella Health, Inc. (Nasdaq: AXLA). He received an M.D. from the University of California, San Francisco and a B.A. in neuroscience from Amherst College.
Lorence Kim, M.D., has served as our Chief Financial Officer since April 2014. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as a Managing Director and co-head of biotechnology investment banking. Dr. Kim has served on the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) since 2014. He received an A.B. in Biochemical Sciences from Harvard University, an M.B.A. in Healthcare Management from the Wharton School of the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine.
Tal Zaks, M.D., Ph.D., has served as our Chief Medical Officer since March 2015. Prior to joining the Company, Dr. Zaks served in senior development positions at Sanofi (NYSE: SNY) from 2010 to 2015, including Senior Vice President and Head of Global Oncology. From July 2008 to May 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. Prior to this, Dr. Zaks spent four years at GlaxoSmithKline (NYSE: GSK) as Director, Clinical Development and Translational Medicine and three years at the National Cancer Institute as a Postdoctoral Fellow. He is currently an Associate Professor of Medicine at the University of Pennsylvania and serves on the board of directors of Adaptimmune Therapeutics plc (Nasdaq: ADAP). Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.
Noubar B. Afeyan, Ph.D., is a co-founder and has served on our board of directors since incorporation, and has served as a chairman of our board of directors since February 2012. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since April 2013, Dr. Afeyan has served on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY) and since October 2010, on the board of Seres Therapeutics, Inc. (Nasdaq: MCRB). He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Evelo Biosciences, Inc. (Nasdaq: EVLO), Kaleido Biosciences, Inc. (Nasdaq: KLDO) and BG Medicine, Inc (OTCMKTS: BGMD). He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (“MIT”) and a B.S. in chemical engineering from McGill University. Dr. Afeyan is currently a visiting lecturer of business administration at Harvard Business School and was previously a senior lecturer at MIT’s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. We believe that Dr. Afeyan’s significant experience co-founding, leading, and investing in numerous biotechnology companies make him qualified to serve on our board of directors.
Stephen Berenson has served as a member of our board of directors since October 2017. Mr. Berenson is a Managing Partner at Flagship Pioneering. Prior to that, Mr. Berenson spent 33 years as an investment banker at J.P. Morgan. During his last twelve years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson also serves as Chairman of the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) and on the board of directors of CiBO Technologies, Inc. Mr. Berenson received an S.B. in mathematics from MIT. We believe that Mr. Berenson is qualified to serve on our board of directors because of his experience in the banking and investment industries.
Robert Langer, Sc.D., has served as a member of our board of directors since December 2010. Dr. Langer has been an Institute Professor at MIT since 2005, and prior to that was a Professor at MIT beginning in 1977. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY), Kala Pharmaceuticals, Inc. (Nasdaq: KALA), and the UK public company Puretech Health plc (LON: PRTC), and previously served on the board of directors of Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Wyeth (NYSE: WYE), Fibrocell Science, Inc. (Nasdaq: FCSC) and Millipore Corporation (acquired by Merck KGaA in 2010). Dr. Langer also served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including his service as chairman from 1999 to 2002. Dr. Langer received his B.S. from Cornell University and his Sc.D. from MIT, both in Chemical Engineering. We believe that Dr. Langer is qualified to serve on our board of directors because of his pioneering academic work, extensive medical and scientific knowledge and experience, and his previous service on public company boards of directors.
Elizabeth Nabel, M.D., has served as a member of our board of directors since December 2015. Dr. Nabel has served as President of Harvard University-affiliated Brigham Health, which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization, since 2010. Dr. Nabel has also been a Professor of Medicine at Harvard Medical School since 2010. Prior to that, Dr. Nabel held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. She is an elected member of the National Academy of Medicine of the National Academy of Sciences. Dr. Nabel currently serves on the board of directors of Medtronic plc (NYSE: MDT) and as a trustee of Tekla Capital Management LLC. We believe that Dr. Nabel is qualified to serve on our board of directors because of her extensive experience in the health care field, including senior positions with a number of research universities and organizations.
François Nader, M.D., has served as a member of our board of directors since December 2019. Dr. Nader currently serves as Chairman of the board of directors of Acceleron Pharma Inc. (Nasdaq: XLRN), Prevail
Therapeutics Inc. (Nasdaq: PRVL) and Talaris Therapeutics, Inc. He also serves on the board of directors of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and as an advisor for SVB Leerink. Dr. Nader is the past Chairman of BioNJ, New Jersey’s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization (BIO), NPS Pharmaceuticals (Nasdaq: NPSP), Advanced Accelerator Applications S.A. (Nasdaq: AAAP), Baxalta Inc. (NYSE: BXLT), Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), Trevena Inc. (Nasdaq: TRVN) and Noven Pharmaceuticals Inc. (Nasdaq: NOVN). Dr. Nader earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive M.B.A. from the University of Tennessee. We believe that Dr. Nader is qualified to serve on our board of directors because of his experience in integrated healthcare markets and medical and regulatory affairs and his service on numerous boards of directors.
Israel Ruiz has served as a member of our board of directors since February 2017. Mr. Ruiz has been the Executive Vice President and Treasurer at MIT since 2011. In this role, Mr. Ruiz oversees all principal administrative and financial functions of MIT. Prior to his current role, Mr. Ruiz served as the Vice President for Finance for MIT from 2007 to 2011 and as a principal for MIT’s Office of Budget and Financial Planning from 2001 to 2007. He currently serves on the board of directors of FM Global and previously served on the board of directors of Fortive Corporation (NYSE: FTV). Mr. Ruiz received a degree in industrial and mechanical engineering from the Polytechnic University of Catalonia and a master’s degree from the MIT Sloan School of Management. We believe that Mr. Ruiz is qualified to serve on our board of directors because of his deep financial and accounting experience as the chief financial officer of MIT.
Paul Sagan has served as a member of our board of directors since June 2018. Mr. Sagan has been a Managing Director at General Catalyst Partners, a venture capital firm, since January 2018, and previously served as an Executive In Residence (XIR) since January 2014. From April 2005 to January 2013, Mr. Sagan served as Chief Executive Officer at Akamai Technologies, Inc. (Nasdaq: AKAM) and was President from May 1999 to September 2010 and from October 2011 to January 2013. He was also a director of Akamai Technologies until 2019. Mr. Sagan currently serves on the board of directors of VMware, Inc. (NYSE: VMW) and was a director of EMC from December 2007 until the acquisition by Dell, Inc. in September 2016. Mr. Sagan received his B.S. from the Medill School of Journalism at Northwestern University. We believe that Mr. Sagan is qualified to serve on our board of directors because of his experience and leadership both in the technology and venture capital fields.
Moncef Slaoui, Ph.D., has served as a member of our board of directors since July 2017. Dr. Slaoui joined GlaxoSmithKline Plc (NYSE: GSK) (“GSK”) in 1988, where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006. He assumed overall responsibility for GSK’s Oncology Business in 2010, for GSK Vaccines in 2011, and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr. Slaoui has advised the U.S. President’s Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology, & Research until January 2011, the PhRMA Foundation Board from 2008 to 2016, and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Université Libre de Bruxelles. We believe that Dr. Slaoui is qualified to serve on our board of directors because of his vast experience in the pharmaceutical industry and various leadership positions.
Sandra Horning, M.D., is nominated to serve as a Class II director on our board. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., from 2009 until her retirement in 2019. Prior to Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at the Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to
2006, she served as President of the American Society of Clinical Oncology. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors. She currently serves as an advisor to EQRx, Inc. Dr. Horning received her M.D. from the University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University. We believe that Dr. Horning is qualified to serve on our board of directors because of her significant experience in the field of oncology and her product development leadership experience.
. . . . . . .
This financial disclosure is from Moderna’s Initial Public Offering (S-1) disclosure filed on Nov. 09, 2018.
It shows the interlocking and seditious relationships that disqualify ALL of these actors in the current Coronavirus Scam-demic… Gates Foundation, DARPA, BARDA, Merck, AstraZeneca (ICI, British government, Queen’s Golden Share) and Moderna’s Israeli chief medical officer Tal Zaks who was a clinical director at GlaxoSmithKline (Wellcome Trust, agent of the Pilgrims Society and the Queen’s Privy Council)
Not so fast Dr. Shiva….we see the Hillary Clinton sycophant you are. But first let’s catch this audience up on some details about your past claims to have invented email.
Shiva’s claims about being ‘the inventor of email’ are bogus, propaganda, Pilgrims Society smokescreen to put a patent claims buffer between IBM/Lotus and everyone else (the then chosen platform for the NWO)
In his 1999 patent, https://www.vashiva.com/pdf/vashiva_pat11.pdf,Shiva only cites IBM Notes, and IBM Domino as prior art that was reviewed. Note: This was THE groupware system that the Highlands Group, DoD Office of Net Assessment and their Pilgrims Society handlers were counting on to implement the “IBM Internet of Things.” Notably, hindsight shows us that at this time, IBM had already founded the IBM Eclipse Foundation (Nov. 29, 2001) with Leader Technologies Ne’er-do-well patent attorney, James P. Chandler, III, and IBM Eclipse was already giving away Leader inventions (including its Leader Mail inventions for use with its social backbone), that they had stolen, to everyone in Silicon Valley, government, education, commerce and military.
This disclosure alone shows the Examiner, or Shiva, or both, were brain dead in their examination of “prior art” to meet the “novel and nonobvious” standards for patentability. Curiously, the “patent wrapper” for this patent does not provide the customary the file drawer for this filing, as it should do.
By the late 1990’s, numerous email systems with the exact features of Inbox, Outbox, etc. Groups, sorting, filters, etc. were in wide use. Those systems included: Leader Mail, Microsoft Outlook, Microsoft Exchange, Novel Groupwise, Novel Groupwise Email, Hotmail, YahooMail, Lotus Notes, Lotus cc:Mail, AT&T Mail, AT&T Access (DOS version), AT&T AccessPlus 3.0 (Windows version), CompuServe (csmail), GEIS (mark400), MCI Mail, SPRINT Mail, X-400, BITNET, AOL Mail (“You’ve got mail.”)
At minimum, this record raises numerous red flags. It is certainly ambiguous. The lack of a “patent wrapper” showing the examiner’s review of the Prior Art begs the question of who is running interference for Shiva? The patent is evidently invalid due to the utter lack of disclosure of significant prior art that the examiner should have used to reject the application as obvious and therefore non-patentable. Certainly Shiva is not justified in saying that he is the “inventor of email.”
This Wikipedia entry is a more accurate reflection of the origins of email.
One serious problem with this Shiva patent is that he does not cite his own prior work, touted on his current website, as prior art. Therefore, his own documents prove this patent bogus.
(Note: We have backups of these documents if they disappear from Shiva’s website now that we are bringing attention to them.)
For example, he shows an UNDATED 1981 alleged Westinghouse entry describing his alleged email design in esquisite detail. This document appears to be fake. Notably, Westinghouse is a Pilgrims Society company that is organically tied to NBC, RCA, Marconi and the Pilgrims Society. At minimum, he should have cited this document as prior art on all of his email filings, which would render them all as obvious… if this document really existed, which we now doubt seriously.
He cites and irrelevant 1978 FORTRAN output that merely mentions email, but there is no association with him.
He shows a newspaper article from Oct. 30, 1980 (p. 8, Sec. 2) of the West Essex Tribune. The article says this project was under “tutelage of Blair Krimmel, head of the math department and the Independent Study program.” Since Shiva does not credit Blair Krimmel as a co-inventor, any subsequent claims are fraudulent (“inequitable conduct”).
His 1981 Westinghouse award discloses:
Such prior art disclosure renders his own work as must-cite prior art in subsequent patent applications—thus invalidating his patent claims as not novel and obvious.
His 1981 MIT article is more evidence that his ideas for email were already widely known, and therefore not patentable.
His 1982 Copyright application only serves to show that he disclosed his work to the public in 1982, thus rendering subsequent patent claims impossible to make (since the public already knew about it). Copyrights and patents are very different intellectual property animals.
His 1982 Dr. Leslie Michelson, Ph.D. article is irrelevant to the subject to email.
His subsequent patents 6668281, 6718367, 6718368 (note the last two were issued on the same day, by the same patent examiners). Very odd, unless a fake portfolio is being created as a buffer against patent enemies of the patent office and Shiva’s handlers.
Conclusion: Shiva’s claim to be “the inventor of email” suffers a definite sulfurous odor.
One of Shiva’s current companies – General Interactive
Whoa….all this on Dr. Shiva just on the first trip down the mines! The miners report seeing all kinds of nuggets regarding Dr. Shiva and his connection to Hillary Clinton, the vaccine world, Microsoft, and Bill Gates lying all over the place.
While you are waiting for our mining reports, get a glimpse of what we saw down there.
Don’t think for one minute that Robert F. Kennedy Jr. is a good guy in this. These are two globalist puppets creating kabuki theater for the vaccine wars. We are going to put both of these vaccine proponents into the bright light of truth.
“Italy sacked it’s vaccine scammers, and put in their place 100 percent new people who are not part of the global conspiracy to destroy people with vaccines, and then subsequently and practically immediately discovered that the vaccines have absolutely nothing they are advertised for, which begs the question: What the hell is really in those shots?
Vaccine advocacy group Corvelva, which is not compromised, spearheaded Italy’s investigation into the vaccine scam.
The Eugenicists are up in arms over Corvelva, a vaccine advocacy group appointed by the Italian government to investigate the vaccines which has now received over $50, 000 in funding to test all the vaccines and see if they are scams. And more, the Eugenicists are upset about WHERE the funding is coming from – top Italian medical science teams are funding Corvelva’s efforts, unlike what this Sott article implies in it’s headline and subsequently tries to state by claiming “scientists” are questioning the Italian government’s actions that the Italian government is off it’s rocker. That’s not what the headline should be. Here is what the headline should be:
FIVE NWO approved science scammers are protesting a vaccine safety investigation being conducted by Italy’s real top scientists who are rapidly and easily uncovering the truth about what the current childhood vaccines really are, and that they are not vaccines at all, they are something else entirely.
As it turns out, all it takes to find out what is really in the vaccines is to break rank, seize a sample of what is being injected into the children, put it in a real lab that is not compromised by kikes, and VOILA!!! suddenly it is known that the vaccines are not at all what they are claimed to be. You can’t do that in the United States. No parent is allowed to walk out the door with a shot that has not been injected into their kids, take it to a lab, and test it. This is NOT ALLOWED. WHY? Italy just got the answer.
The MSM is holding this topic by the gills at arm’s length like a diseased fish because of what Corvelva has found – that the vaccines really don’t have anything they are advertised for and are instead full on scams.
You can’t find a legitimate MSM report on this topic. Instead, the reports are all slander, calling Italians stupid, backwards, “conspiratorial”, against “established science” and anything else they can muster, and they HAVE TO because the vaccine eugenics programs are one of their greatest treasures, with carefully placed totally compromised despicable hateful and soulless people in all key positions to keep a lid on the scam and allow the destruction of our children proceed without a hitch.
Italy just blew the lid off the vaccine scam, and this one is not going away folks, Italy is NOT ZIMBABWE, they are clearly a first world country that can speak with authority. So the MSM is now trying to slander Italy because Italy uncovered one of kikedom’s NWO eugenics plots.
As if we did not all know the vaccines were wrecking our kids all along, – Gee, one in 35 kids now gets autism and “nobody can figure out why??” They know damn well at Newsweek, Sott and more. The entire shadow government KNOWS IT and now that Italy broke free of their grasp they are trying to bury it. Instead, they ought to just put a fork in it. THANKS ITALY for finally putting it in print from an official level. We knew it all along, but it is nice to get real confirmation from the top ranks of a first world government.”
Please correct all those fake news channels calling it a “soft coup.” It was a hard coup.
It was a British attempt to overthrow the United States President.
It was conducted from the highest levels of the British inner Fleet Street cabal from the Queen, her Privy Council, the Pilgrims Society, and the media. This also includes: Alison Saunders’ conspiracy with Bruce and Nellie Ohr, Arvinder Sambei with Robert Mueller, Robert Hannigan with John Brennan, Richard Dearlove, Mark Malloch-Brown, George Soros, Nick Clegg, Geoffrey Pattie.
Our AFI-AIM researchers are pulling out the TRUTH and the EVIDENCE daily from our research mines.
Call it what it is: ACT OF WAR
The British Monarch is enemy of the entire world. We must call for immediate action against the Queen and her co-conspirators for their crimes against humanity. All patriots around the world are called to action to free their nations and its citizens from the tyrannical rule of the British Empire. Historical facts don’t lie.
Correspondent. (Jul. 23, 1909). EMPIRE PRESS UNION formed, published Sep. 07, 1909, Issue No. 14622, Dunedin, New Zealand via National Library of New Zealand, Ref. No. ODT19090907.2.6. Otago Daily Times.
Henry S. Wellcome. (Jun. 01, 1909 – ca. Jul. 1909). THE EVOLUTION OF JOURNALISM ETCETERA – International / Imperial Press Conference, 1909, Great Britain (incl. Lord Burnham, Sirs Edward and Harry Levy-Lawson). Burroughs Wellcome. FULLY INDEXED, BOOKMARKED, SEARCHABLE. 27.1 MB.
The White Supremacists who ran cover for the establishment of MI5 and MI6 using the Imperial Press Conference, 1909 to recruit War Correspondents (Daily Telegraph, Daily Mail, Reuters, Financial Times, the Times, Manchester Guardian, Daily Express, BBC, New York Times, Chicago Tribune, Daily Mirror, Fleet Street, etc.) and (propaganda) writers from across the Commonwealth.
“We seem, since the inauguration of the Imperial Department of Criminal Intelligence, to be on the verge of constituting a Secret Police Force, and no innovation could be more dangerous and more liable to become a weapon of oppression with the material we are obliged to work through.”
HC Deb 29 July 1909 vol 8 cc1381-4321381 (The Day the Empire Press Union was formed by delegates from the Imperial Conference just concluded)
Motion made, and Question proposed, “That a sum not exceeding £66,171 be granted to His Majesty to complete the sum necessary to defray the charge which will come in course of payment during the year ending on the 31st day of March, 1910, for the Salaries and Expenses in the Department of His Majesty’s Treasury and Subordinate Departments, including expenses in respect of advances under the Light Railways Act, 1896.”
Let’s face it, President Trump may be a brilliant builder, billionaire, and deal-maker, but we have all seen what he eats – fast food and diet coke. Anyone knowledgeable about food, nutrition, and health would not be ingesting these poisons. Just coming after his approval of 5G, 6G, and higher, this executive order gives a green light for our food industry to become total poison.
We are huge supporters of POTUS just like many of our readers, but these decisions – from creating 5G killing fields to Monsanto killing fields, is not acceptable to us.
Because we are leaving town, – we only have time for this quick blast to tell you RED ALERT RED ALERT. As AIM patriot AIM Patriot Denise writes us this morning:
I am writing because of the new executive order 13874 was signed by our President 6/11/2019 and I do not understand it. It seems that President Trump is saying it is alright to develop and send out to the world genetically engineered food but I could be misunderstanding.
You all are so smart that I was hoping you could take a look and let us know what you think.
I know you are busy so thank you so much in advance.
Denise, when we get back we will be writing an expose on why this is a horrible decision and why this executive order puts all Americans in jeopardy with even more health problems. Perhaps the president doesn’t understand what happens with GMOs.
Let’s use one simple example. McDonald’s doesn’t like how potatoes and apples brown when they are cut. Shortens the “shelf life”. The reason that fruits and vegetables brown is because the natural enzymes in the plant break down the pulp. Enzymes are extremely important in digestion and breaking down plant life. So the frankenfood industry creates a potato and apple that don’t brown. They genetically remove the plants’ enzymes. Now those potatoes and apples can last forever without turning brown.
Or take a look at the bag of veggies that you bought last month and are still in the bag…but haven’t browned a bit. Thanks to the frankenfood industry for removing the enzymes and irradiating the produce, the vegetables will now have long shelf lives.
The serious, life-threatening problem with this is that you eat these products and you cannot digest them. They have no enzymes so they cannot be properly eliminated from your body. The waste product sits in your gut and becomes toxic, creating all kinds of physical problems in your body.
We have written about this in one of our lessons from the ASCEND diet. Check it out: Clearing the Hara Chakra. You will also learn what happened in the Pottenger cat study when cats ate foods without enzymes over a few generations – they became sterile!
Is that what President Trump and his administration are doing? Is he on a mission to keep Americans sick from frankenfoods up to a point that our young people will not reproduce? This coupled with his stand on 5G has us fuming.
Please start contacting the White House with your concern over this insanity. Contact White House.We must do a better job educating President Trump on this matter and we must demand a full retraction of this horrific executive order.
When we get back we will prepare a white paper and a few audios to help you educate and enlighten your circle of influence on how bad this will be for all Americans – living and future generations.
In the meantime, Vladimir Putin is protecting his citizenry from frankenfoods. Soon, all health-conscious Americans will be buying agricultural products from Russian organic farms. Vladimir Putin cares about the future health of his people. With the signing of this executive order and the continued promotion of 5G, it is clear that this administration is intent on sickening and killing us.